Sustained reduction of exercise perfusion defect extent and severity with isosorbide mononitrate (Imdur) as demonstrated by means of technetium 99m sestamibi

Journal of Nuclear Cardiology

Volumn 7, Issue 4, 2000, Pages 342-353

  Lewin, Howard C ^a,b   Hachamovitch, Rory ^a,b   Harris, Alan G ^a,b   Williams, Cyndi ^a,b   Schmidt, Juli ^a,b   Harris, Michael ^c   Van Train, Kenneth ^a,b   Siligan, Gerrard ^a,b   Berman, Daniel S ^a,b  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Integrated Therapeutics Group   (United States)

Author keywords

Coronary artery disease; Exercise induced ischemia; Isosorbide 5 mononitrate; Myocardial perfusion SPECT; Quantitative analysis; Technetium 99m sestamibi

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; AUTOMATION; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFECT; EXERCISE TEST; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE DIAGNOSIS; SCINTIANGIOCARDIOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSTAINED RELEASE FORMULATION; TREADMILL EXERCISE;

EID: 0033846321     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1067/mnc.2000.106966     Document Type: Article

References (44)

1. Medical therapy of stable angina pectoris
2. Oral isosorbide dinitrate in angina pectoris: Comparison of duration of action and dose-response relation during acute and sustained therapy
3. Acute and long-term antianginal efficacy of continuous twenty-four hour application of transdermal nitroglycerin
4. Avoidance of tolerance and lack of rebound with intermittent dose-titrated transdermal glyceryl trinitrate
5. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate
6. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina
7. Intermittent transdermal nitroglycerin monotherapy in stable, exercise-induced angina: A comparison with a continuous schedule
8. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris
9. Prognostic significance of silent myocardial ischemia on a thallium stress test
10. Significance of silent myocardial ischemia during exercise testing in patients with coronary artery disease
11. Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patents with stable coronary artery disease
12. Silent ischemia during daily life is an independent predictor of mortality in stable angina
13. Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients
14. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina
15. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: Results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography
16. Effects of titrated beta blockade (metoprolol) on silent myocardial ischemia in ambulatory patients with coronary artery disease
17. Effect of diltiazem on symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and during exercise
18. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms
19. Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil
20. Diltiazem, nifedipine, and their combination in patients with stable angina pectoris: Effects on angina, exercise tolerance, and the ambulatory electrocardiographic ST segment
21. Incremental value of simultaneous assessment of myocardial function and perfusion with technetium-99 sestamibi for prediction of extent of coronary artery disease
22. Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomograph: A clinical validation study
23. Patient motion in thallium-201 myocardial SPECT imaging: An easily identified frequent source of artifactual defect
24. Reproducibility of quantitative rest thallium-201/stress Tc-99m sestamibi dual isotope SPECT for assessment of perfusion defect extent and reversibility
25. Reproducibility of stress redistribution thallium-201 SPECT quantitative indices of hypoperfused myocardium secondary to coronary artery disease
26. High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography
27. Short-and long-acting oral nitrates for stable angina pectoris
28. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound
29. Quantitative analysis of tomographic stress thallium-201 myocardial perfusion scintigrams: A multicenter trial
30. Technical aspects of myocardial SPECT imaging with technetium-99m sestamibi
31. Quantitative same-day rest stress technetium-99m sestamibi SPECT: Definition and validation of stress normal limits and criteria for abnormality
32. Multicenter trial validation for quantitative analysis of same-day rest-stress technetium-99m sestamibi myocardial tomograms
33. Operator-less processing of myocardial perfusion SPECT studies
34. Quantitative assessment of stress defect extent and reversibility on rest Tl-201/stress Tc-99m sestamibi dual isotope myocardial perfusion SPECT: A prospective validation
35. Quantitative assessment of reversibility for rest Tl-201 stress Tc-99m sestamibi separate acquisition dual isotope myocardial perfusion SPECT: Development and prospective validation
36. A quantitative program for assessment of perfusion defect severity in stress Tc-99m sestamibi SPECT: Validation by comparison to expert visual interpretation
37. Clinical validation of automatic quantitative defect size in rest Technetium-99m-sestamibi myocardial perfusion SPECT
38. Reproducibility of quantitative rest thallium-201/stress Tc-99m sestamibi dual isotope SPECT for assessment of perfusion defect extent and reversibility
39. Exercise myocardial perfusion SPECT in patients without known coronary artery disease
40. Reduction of exercise-induced myocardial perfusion defects by isosorbide-5-mononitrate: Assessment using quantitative Tc-99m-MIBI-SPECT
41. Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary artery disease
42. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: Reversibility by nitroglycerin
43. Preferential dilation of recipient coronary arteries of the collateral circulation by intracoronary administration of nitroglycerin
44. Myocardial ischemia caused by distal coronary artery constriction in stable angina pectoris